Terms & conditions
Terms & conditions
This website is designed in the United Kingdom and is for information purposes only and is not an advertisement. Nothing on this site constitutes a binding offer to perform any service.
Although we have taken care over what is said in this website, any advice contained in the website is of a generic nature only. Any reliance by you on such advice or any information in the site is entirely at your own risk and we do not accept any liability to any person who relies on it.
We are not responsible for the content of any other site (website, blog, social media or other), including any site through which you may have gained access to this website or to which you may gain access from this website. We do not accept any liability in connection with any such sites or links.
You are responsible for obeying all applicable copyright laws. We permit you to make copies of this site as necessary incidental acts during your viewing of it; and you may take a print for your personal use of so much of the site as is reasonable for private purposes, but you must not otherwise copy it, use it or re-publish it in whole or in part (including by linking or framing) without this “Disclaimer” section nor without first obtaining written consent from I C Consultants Ltd.
© I C Consultants Ltd. All rights reserved, and all moral rights are asserted and reserved.
Latest news, insights and events
Live, ISUOG approved interactive session by European and Asian experts on the latest research on managing complex MCDA twins. For fetal medicine experts, radiologists, obstetricians, sonographers, specialist midwives, neonatologists and trainees in these fields. Starts 12 noon (UK) read more
The partnership was signed last week at Imperial with representatives from Imperial’s research team, City Proton including Ken Anderson, Chairman, Imperial Consultants and Imperial Innovations, as well as Professor James Stirling, Provost of Imperial College London. read more
Australian pharmaceutical company, Spinifex Pharmaceuticals (“Spinifex”) has recently presented the clinical development of their lead product at the 14th World Congress of Pain®, highlighting the success of consultancy through Imperial Consultants. read more